Handelsavisen
prelaunch
Companies ›Healthcare ›PRAX.O
PR
PRAX.O — NASDAQ Biotechnology

Prax.O

$307,83
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
7,8B USD
P/E
—
EV / Rev
991,4x
Div yield
—
Op margin
—
ROE
-34,5 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$307,75
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

PRAX.O is a biotechnology company within the Health Care sector that currently reports zero revenue and operates with a negative operating income, relying on equity financing and cash reserves to fund its activities.

Business. PRAX.O is a biotechnology company within the Health Care sector that currently reports zero revenue and operates with a negative operating income, relying on equity financing and cash reserves to fund its activities.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY19 analysts
17 buy1 hold1 sell
Avg 12m price target603,89

Analyst recommendations

19 analysts · consensus Buy
Buy17
Hold1
Sell1
12-month price target
603,89
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
19 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-34,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PRAX.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PRAX.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    PRAX.O is a biotechnology company within the Health Care sector that currently reports zero revenue and operates with a negative operating income, relying on equity financing and cash reserves to fund its activities.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    The company maintains a conservative capital structure with a debt-to-equity ratio of 0.0, indicating no interest-bearing debt on the balance sheet. Total equity stands at $878.1 million, supported by cash and equivalents of $357.3 million against total assets of $937.9 million. The current ratio is not explicitly provided, but the absence of debt and significant cash holdings suggest adequate short-term liquidity, consistent with the "low" liquidity risk assessment. The market capitalization is $7.76 billion, resulting in a price-to-book ratio of 8.83, which reflects the market's premium on the company's intangible assets and future potential rather than current book value.

    Profitability metrics are negative, with a return on equity of -34.54% and a return on assets of -32.33%, driven by an operating income of -$326.2 million and net income of -$303.3 million. The company reports zero revenue, indicating it is in a pre-commercial or early-stage development phase. The negative EV/EBITDA of -22.68 is not meaningful in a traditional valuation context due to the lack of earnings. These figures are typical for early-stage biotechnology firms that prioritize research and development over immediate profitability.

    Key takeaways
    • The company has zero revenue and negative profitability, typical of early-stage biotechnology firms.
    • Strong balance sheet with $357.3 million in cash and no debt, resulting in low liquidity and dilution risks.
    • High market valuation with a P/B ratio of 8.83 and market cap of $7.76 billion, reflecting future growth expectations.
    • Bullish analyst sentiment with a mean price target of $603.89 and strong buy/buy recommendations dominating.
    • Lack of historical financial data and segment details limits deeper fundamental analysis.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-04-06
    Q1 2026 · Quarter highlights
    Open report →

    Operating income −41,7% YoY; Net income −33,6% YoY.

    Revenue—
    Operating income-$105.9M−41,7 % YoY
    Net income-$92.6M−33,6 % YoY
    Free cash flow-$92.6M−33,7 % YoY
    EPS—
    Operating cash flow-$86.2M−62,5 % YoY
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income-$105.9M
    Net income-$92.6M
    Balance sheet
    Total assets$1.46B
    Total liabilities$50.2M
    Total equity$1.41B
    Cash & equivalents$536.3M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$86.2M
    CapEx-$62.0k
    Free cash flow-$92.6M
    SBC—
    Highlights
    • ▍Operating income −41,7% YoY
    • ▍Net income −33,6% YoY
    • ▍Free cash flow −33,7% YoY

    Valuation TTM

    Market price
    $307,83
    Market cap
    $7.76B
    Enterprise valueⓘ
    $7.40B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    991.4x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    8.8x
    P / Tangible bookⓘ
    8.8x
    Tangible book
    $878.1M
    Net cashⓘ
    $357.3M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    -32.3%
    ROEⓘ
    -34.5%
    Cash conversionⓘ
    82.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships4 disclosed relationships · 2 types · extracted from filings & disclosures
    Partners1
    Ionis Pharmaceuticals IncIONS.OPartner95%Source ↗
    Subsidiaries3
    EX21:32d3153dcc3eEX21:32d3153dcc3eSubsidiarie97%
    EX21:7efb3ad131c5EX21:7efb3ad131c5Subsidiarie97%
    EX21:f9f15f88ae6eEX21:f9f15f88ae6eSubsidiarie97%

    Supply chain

    Vendors → PRAX ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSPRAXPRAXPrax.O4 entitiesIonis Pharmaceuticals UnclassifiedUS
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 33 %
    EPS
    Consensus EPS
    -15,16
    Predicted surprise
    -0,02
    Beat probability
    33 %
    Analysts
    19
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-08-02 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-15,16
    Revenue—no estimate—no estimate2,6M USD
    Operating income—no estimate—no estimate-477,8M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-21 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution19 analysts
    Strong buy7
    Buy10
    Hold1
    Sell0
    Strong sell1
    12-month price target$603,89 · Median $550,00
    Low $162,00High $1 201,00
    Operating income · consensus-477,8M USD
    EPS surprise
    +11,1 %
    reported vs consensus · beat
    Revenue surprise
    −100,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$162,00
    Mean$603,89
    Median$550,00
    High$1 201,00
    Spot$307,83
    +96.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-34,5 %Below median
    D/E0,00Above median
    Cash Conv0,82Above median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-21 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 43 882 sh2 exercises · 15 grants13 insiders
    • DeSimone JillDirector · Stock Option (Right to Buy) → Common StockDisposed 8 566 @ $44,25exercise · 2026-06-24
    • DeSimone JillDirector · Stock Option (Right to Buy) → Common StockDisposed 3 034 @ $147,30exercise · 2026-06-24
    • KINDLER JEFFREY BDirector · Stock Option (Right to Buy) → Common StockAcquired 648 @ $240,66grant · 2026-06-10
    • Norden GregoryDirector · Stock Option (Right to Buy) → Common StockAcquired 648 @ $240,66grant · 2026-06-10
    • DeSimone JillDirector · Stock Option (Right to Buy) → Common StockAcquired 648 @ $240,66grant · 2026-06-10
    • YOUNG WILLIAM DDirector · Stock Option (Right to Buy) → Common StockAcquired 648 @ $240,66grant · 2026-06-10
    • Chodakewitz JeffreyDirector · Stock Option (Right to Buy) → Common StockAcquired 648 @ $240,66grant · 2026-06-10
    • Arbuckle Stuart ADirector · Stock Option (Right to Buy) → Common StockAcquired 648 @ $240,66grant · 2026-06-10
    • Cudkowicz Merit EsterDirector · Stock Option (Right to Buy) → Common StockAcquired 648 @ $240,66grant · 2026-06-10
    • MITCHELL DEAN JDirector · Stock Option (Right to Buy) → Common StockAcquired 648 @ $240,66grant · 2026-06-10
    • Arbuckle Stuart ADirector · Stock Option (Right to Buy) → Common StockAcquired 224 @ $319,57grant · 2026-02-06
    • KINDLER JEFFREY BDirector · Stock Option (Right to Buy) → Common StockAcquired 224 @ $319,57grant · 2026-02-06
    • Kelly Timothy EdwinChief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 7 040 @ $294,38grant · 2026-01-08
    • Nemiroff AlexGeneral Counsel and Secretary · Stock Option (Right to Buy) → Common StockAcquired 5 500 @ $294,38grant · 2026-01-08
    • Mastrocola LaurenPrincipal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 7 500 @ $294,38grant · 2026-01-08
    • Souza MarcioDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 22 110 @ $294,38grant · 2026-01-08
    • Sniecinski MeganChief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 7 700 @ $294,38grant · 2026-01-08

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • PRAXIS PRECISION MEDICINES, INC. Market data — financials · 2026-08-02
    • Praxis Precision Medicines Inc Market data — analyst estimates · 2026-08-02
    • Praxis Precision Medicines Inc Market data — ESG · 2026-08-02
    • PRAX.O HA canonical relationships · 2026-08-02

    Ownership & reference

    Top holders

    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,04 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,04 %$696M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,03 %$229M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,02 %$0M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,02 %$89M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,02 %$41M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,02 %$269M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,01 %$27M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$210M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$69M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,01 %$56M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$285M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$73M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,01 %$19M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,01 %$11M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$24M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,01 %$431M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$35M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$28M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$20M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$5M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$8M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$10M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$10M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$54M
    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,00 %$2M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$4M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$2M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling0 buys · 12 sellsnet -$3,6M13 insiders · last 365d
    • Souza MarcioDirector, Chief Executive Officer · Common StockOther 2 600 · 2026-07-08
    • Souza MarcioDirector, Chief Executive Officer · Common StockOther 20 521 · 2026-07-08
    • DeSimone JillDirector · Common StockOther 3 034 @ $147,30$447K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 837 @ $315,70$264K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 1 279 @ $314,90$403K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 504 @ $313,66$158K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 1 004 @ $312,83$314K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 2 854 @ $311,91$890K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 1 750 @ $310,89$544K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 999 @ $309,38$309K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 1 240 @ $308,24$382K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 683 @ $306,77$210K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 10 @ $301,44$3K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 320 @ $305,31$98K · 2026-06-24
    • DeSimone JillDirector · Common StockSold 120 @ $303,13$36K · 2026-06-24
    • DeSimone JillDirector · Common StockOther 8 566 @ $44,25$379K · 2026-06-24
    • Cudkowicz Merit EsterDirector · Common StockOther 1 371 · 2026-06-10
    • MITCHELL DEAN JDirector · Common StockOther 1 371 · 2026-06-10
    • Norden GregoryDirector · Common StockOther 1 371 · 2026-06-10
    • KINDLER JEFFREY BDirector · Common StockOther 1 371 · 2026-06-10
    • Arbuckle Stuart ADirector · Common StockOther 1 371 · 2026-06-10
    • Chodakewitz JeffreyDirector · Common StockOther 1 371 · 2026-06-10
    • YOUNG WILLIAM DDirector · Common StockOther 1 371 · 2026-06-10
    • DeSimone JillDirector · Common StockOther 1 371 · 2026-06-10
    • Mastrocola LaurenPrincipal Accounting Officer · Common StockOther 127 @ $167,94$21K · 2026-05-14

    Short positioning

    3.8Mshares short-5.6% vs prior
    9.21days to cover
    73.4%short of daily vol
    8.3Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PRAX.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob33 %Surprise-0,02M&A prob3 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    PRAXIONS.OEX21:32dEX21:7efEX21:f9fBiotechnology
    This companySectorPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 65.9%Derived (calculated)
    • Return on equity (FY 2025-12-31): -34.5%Derived (calculated)
    • Return on assets (FY 2025-12-31): -32.3%Derived (calculated)
    • Current ratio (FY 2025-12-31): 10.22xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.07xDerived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -32.0%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -32.0%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -65.6%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -89.0%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -63.0%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 75.3%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 97.1%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 94.1%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 58.7%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
    • Current liabilities (annual): USD 59.77MSEC XBRL filing
    • Current assets (annual): USD 610.91MSEC XBRL filing
    • Shares outstanding (annual): 25.2MSEC XBRL filing
    • Operating cash flow (annual): USD -249.07MSEC XBRL filing
    • Total operating expenses (annual): USD 326.2MSEC XBRL filing
    • Net income (annual): USD -303MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -13SEC XBRL filing
    • Cash & equivalents (annual): USD 357.33MSEC XBRL filing
    • Revenue (annual): USD 0SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-08INSIDERSouza Marcio transacted 2.6k sh — Director, Chief Executive Officer
    2026-07-08INSIDERSouza Marcio transacted 20.5k sh — Director, Chief Executive Officer
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-26 03:13 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-24 00:00 UTCINSIDER32 insider transactions — 2026-06 · net sell $2.8M 10 derivative
    2026-06-24INSIDERDeSimone Jill transacted 3.0k sh — Director ~$447k
    2026-06-24INSIDERDeSimone Jill sold 837 sh — Director ~$264k
    2026-06-24INSIDERDeSimone Jill sold 1.3k sh — Director ~$403k
    2026-06-24INSIDERDeSimone Jill sold 504 sh — Director ~$158k
    2026-06-24INSIDERDeSimone Jill sold 1.0k sh — Director ~$314k
    2026-06-24INSIDERDeSimone Jill sold 2.9k sh — Director ~$890k
    2026-06-24INSIDERDeSimone Jill sold 1.8k sh — Director ~$544k
    2026-06-24INSIDERDeSimone Jill sold 999 sh — Director ~$309k
    2026-06-24INSIDERDeSimone Jill sold 1.2k sh — Director ~$382k
    2026-06-24INSIDERDeSimone Jill sold 683 sh — Director ~$210k
    2026-06-24INSIDERDeSimone Jill sold 10 sh — Director ~$3k
    2026-06-24INSIDERDeSimone Jill sold 320 sh — Director ~$98k
    2026-06-24INSIDERDeSimone Jill sold 120 sh — Director ~$36k
    2026-06-24INSIDERDeSimone Jill transacted 8.6k sh — Director ~$379k
    2026-06-24INSIDERDeSimone Jill disposed of 8.6k sh Stock Option (Right to Buy) — Director
    2026-06-24INSIDERDeSimone Jill disposed of 3.0k sh Stock Option (Right to Buy) — Director
    2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-12FILING8-K filing →
    2026-06-10INSIDERCudkowicz Merit Ester transacted 1.4k sh — Director
    2026-06-10INSIDERMITCHELL DEAN J transacted 1.4k sh — Director
    2026-06-10INSIDERNorden Gregory transacted 1.4k sh — Director
    2026-06-10INSIDERKINDLER JEFFREY B transacted 1.4k sh — Director
    2026-06-10INSIDERArbuckle Stuart A transacted 1.4k sh — Director
    2026-06-10INSIDERChodakewitz Jeffrey transacted 1.4k sh — Director
    2026-06-10INSIDERYOUNG WILLIAM D transacted 1.4k sh — Director
    2026-06-10INSIDERDeSimone Jill transacted 1.4k sh — Director
    2026-06-10INSIDERKINDLER JEFFREY B acquired 648 sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERChodakewitz Jeffrey acquired 648 sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERMITCHELL DEAN J acquired 648 sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERCudkowicz Merit Ester acquired 648 sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERDeSimone Jill acquired 648 sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERYOUNG WILLIAM D acquired 648 sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERNorden Gregory acquired 648 sh Stock Option (Right to Buy) — Director
    Showing the 40 most recent of 72 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage